Labcorp Holdings Inc

Price recently plunged below the 9- and 20-day EMAs after a support failure but found a bounce at the rising 50-day SMA. Despite short-term downside pressure, the Stage 2 advancing regime and long-term uptrend support a medium-term bullish bias. Execution is deferred—stalking for reclaim and acceptance above the 9/20 EMAs or stabilization near the 50-day SMA before initiating new buys.

• ↑Q2 revenue $3.73B (+5.8% YoY); adjusted EPS $4.99 (+15% YoY)
• ↑Operating margin improved 70bps to 15.8% in Q2
• ↓Negative earnings yield and weak revenue growth metrics